by: Parent Project Muscular Dystrophy
ITF Therapeutics recently joined PPMD for a webinar to provide the Duchenne community with an opportunity to meet members of the ITF Therapeutics team to learn more about their organization and next steps to support the availability of DUVYZAT.
ITF Therapeutics outlined next steps in the launch of DUVYZAT, including work on insurance policy education and coverage, healthcare provider education, gathering community feedback on services and programs, transitioning clinical trial participants to commercial product, and commercial product availability, which ITF expects later this year. The company then answered questions from the community on a variety of topics.
